Detoxifying agents for antineoplastic treatment ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1
337Homocystinuria1

299. Cystic fibrosis


Clinical trials : 1,695 Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-020516-11-IT
(EUCTR)
16/09/201028/09/2010EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - NDEXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY
MedDRA version: 9.1;Level: PT;Classification code 10033628
MedDRA version: 9.1;Classification code 10011762
Trade Name: PREFOLIC*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML
INN or Proposed INN: Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy

337. Homocystinuria


Clinical trials : 16 Drugs : 19 - (DrugBank : 7) / Drug target genes : 2 - Drug target pathways : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-000614-21-IT
(EUCTR)
11/12/200605/10/2007A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria - NDA multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria - ND Homocystinuria
MedDRA version: 6.1;Level: PT;Classification code 10020365
Trade Name: PREFOLIC 15*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
ZAMBON GROUPNULLNot RecruitingFemale: yes
Male: yes
22Hungary;United Kingdom;Italy;Austria